Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies (Q39993475)

16 September 2017

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies (English)

1 reference

16 September 2017

A Quintás-Cardama

1

1 reference

16 September 2017

W Tong

2

1 reference

16 September 2017

T Manshouri

3

1 reference

16 September 2017

F Vega

4

1 reference

16 September 2017

P A Lennon

5

1 reference

16 September 2017

J Cools

6

1 reference

16 September 2017

D G Gilliland

7

1 reference

16 September 2017

F Lee

8

1 reference

16 September 2017

J Cortes

9

1 reference

16 September 2017

H Kantarjian

10

1 reference

16 September 2017

G Garcia-Manero

11

1 reference

16 September 2017

10 April 2008

1 reference

16 September 2017

1 reference

16 September 2017

22

1 reference

16 September 2017

6

1 reference

16 September 2017

1117-1124

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.80

16 September 2017

0 references

cites work

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Amplification of the ABL gene in T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

NUP214-ABL1 in adult T-ALL: the GMALL study group experience.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

The human CAN protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.80

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.80

1 reference

Dimensions Publication ID

16 September 2017

0 references

1 reference